Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.

Inclusion Criteria:

• BMI >/= 25 to </= 40 kg/m2
• Type 2 Diabetes Mellitus and on a stable dose of metformin
• Hypertriglyceridemia

Exclusion Criteria:

• Significant abnormalities in medical history, clinical examination or clinical testing
• Use of oral anti-diabetic medication other than metformin within 3 months prior to dosing
• History of outpatient insulin use for more than 2 weeks in the last year